Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.

A Multi-center, Double-blind, Randomized, Parallel, Active-controlled Phase III Trial to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.

To evaluate the efficacy and safety of botulinum toxin type A for injection INI101 compared to BOTOX® in subjects with moderate to severe glabellar lines.

Inclusion Criteria:

1. Adult male or female participants aged between 19 and 65 years old.
2. Participants whose glabellar line score was 2 (moderate) or higher of glabellar line score at maximum frown based on the investigator's judgment at screening and randomization.
3. Participants who voluntarily gave a consent in writing to participate in the clinical study with full knowledge of details of the study after listening to them.
4. Participants who can understand and comply with the procedures and visit schedules of the study.

Exclusion Criteria:

1. Systemic neuromuscular junction disorders (e.g., myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, hereditary motor neuropathy, etc.)
2. History of blepharoplegia or ptosis
3. Prominent facial asymmetry
4. Glabellar lines that are physically difficult to be improved, such as the case where the lines are not removed by hands
5. Participants who have received any drugs that can act as a systemic muscle relaxant within 4 weeks prior to screening
6. Participants who have received anticoagulants, anti-platelet agents, or systemic NSAIDs within 7 days prior to administration of investigational products (however, low-dose aspirin [325 mg/day or less] administered for antithrombotic purposes is acceptable)
7. Participants who have participated in other clinical trials of a drug/medical device within 30 days from participating in this clinical study and have been administered/treated with the investigational product/medical device
8. Participants deemed ineligible for this study for other reasons based on the investigator's judgment